Ho becomes CFO at Third Harmonic
Plus updates from Orna, Prelude, Joseph Damond and more
Third Harmonic Bio Inc., which is developing oral KIT inhibitors for allergy and inflammation, hired Robert Ho as CFO. Ho was most recently CFO at Neoleukin Therapeutics Inc. (NASDAQ:NLTX), and before that, he was a senior director of finance at DaVita Inc. (NYSE:DVA) and VP in the investment banking division at Morgan Stanley, where he executed more than $9 billion in financings and participated in M&A transactions of more than $5 billion.
Orna Therapeutics Inc. hired William Shen as CBO. Shen joins from Virtuoso Therapeutics Inc., where he was COO. He was VP, head of business development at Biogen Inc. (NASDAQ:BIIB), before which he was M&A lead at Bristol Myers Squibb Co. (NYSE:BMY), and led the acquisitions of IFM Therapeutics LLC and Cardioxyl Pharmaceuticals Inc. Seeded by MPM Capital, Orna raised $80 million in series A round to develop circular RNA therapies for cancer and genetic diseases. ...